## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A compound comprising a peptide moiety, a spacer moiety, and a water-soluble polymer moiety wherein the spacer moiety is between the peptide moiety and the water-soluble polymer moiety and having the structure:

$$-NH-(CH_2)_\alpha-[O-(CH_2)_\beta]_\gamma-O_\delta-(CH_2)_\varepsilon-Y-$$

wherein $\alpha$, $\beta$, $\gamma$, $\delta$,and $\varepsilon$ are each integers whose values are independently selected.

2. (Original) The compound of claim 1, wherein

$\alpha$ is an integer, $1 \leq \alpha \leq 6$;

$\beta$ is an integer, $1 \leq \beta \leq 6$;

$\varepsilon$ is an integer, $1 \leq \varepsilon \leq 6$;

$\delta$ is 0 or 1;

$\gamma$ is an integer, $0 \leq \gamma \leq 10$; and

Y is either NH or CO.

3. (Original) The compound of claim 2, wherein $\gamma > 1$ and $\beta = 2$.

4. (Original) The compound of claim 1 wherein

$\alpha = \beta = \varepsilon = 2$;

$\gamma = \delta = 1$; and

Y is NH.

5. (Original) The compound of claim 1 wherein the water-soluble polymer moiety is a poly(ethylene glycol) moiety.

6. (Currently amended) The compound of claim 5 wherein the molecular weight of the poly(ethylene glycol) moiety is ~~more than~~ 20 KDalton or more.

7. (Original) The compound of claim 5, wherein the poly(ethylene glycol) moiety is linear.

8. (Original) The compound of claim 5, wherein the poly(ethylene glycol) moiety has a molecular weight from 20 to 40 KDalton.

9. (Original) The compound of claim 5, wherein the poly(ethylene glycol) moiety has polydispersity value ($M_w/M_n$) of less than 1.20.

10. (Original) The compound of claim 1, wherein the peptide moiety is peptide monomer comprising a single peptide.

11. (Original) The compound of claim 1, wherein the peptide moiety is a peptide dimer comprising two peptides linked by a linker moiety.

12. (Original) The compound of claim 10 or 11, wherein each peptide comprises no more than 50 amino acid monomers.

13. (Original) The compound of claim 12, wherein each peptide comprises between about 10 and 25 amino acid monomers.

14. (Original) The compound of claim 1, wherein the peptide moiety comprises one or more peptides which bind to erythropoietin-receptors.

15. (Original) The compound of claim 1, wherein the peptide moiety comprises one or more peptides which bind to thrombopoietin-receptors.

16. (Original) A pharmaceutical composition comprising

(a) a compound comprising a peptide moiety, a spacer moiety, and a water-soluble polymer moiety wherein the spacer moiety is between the peptide moiety and the water-soluble polymer moiety and having the structure

$$-NH-(CH_2)_\alpha-[O-(CH_2)_\beta]_\gamma-O_\delta-(CH_2)_\varepsilon-Y-$$

wherein $\alpha$, $\beta$, $\gamma$, $\delta$,and $\varepsilon$ are each integers whose values are independently selected; and

(b) one or more pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.

17. (Original) The composition of claim 16, wherein

$\alpha$ is an integer, $1 \leq \alpha \leq 6$;

$\beta$ is an integer, $1 \leq \beta \leq 6$;

$\varepsilon$ is an integer, $1 \leq \varepsilon \leq 6$;

$\delta$ is 0 or 1;

$\gamma$ is an integer, $0 \leq \gamma \leq 10$; and

Y is either NH or CO.

18. (Original) The composition of claim 17, wherein $\gamma > 1$ and $\beta = 2$.

19. (Original) The composition of claim 16 wherein

$\alpha = \beta = \varepsilon = 2$;

$\gamma = \delta = 1$; and

Y is NH.

20. (Original) The composition of claim 16 wherein the water-soluble polymer moiety is a poly(ethylene glycol) moiety.

21. (Currently amended) The composition of claim 20 wherein the molecular weight of the poly(ethylene glycol) moiety is ~~more than~~ 20 KDalton or more.

22. (Original) The composition of claim 20, wherein the poly(ethylene glycol) moiety is linear.

23. (Original) The composition of claim 20, wherein the poly(ethylene glycol) moiety has a molecular weight from 20 to 40 KDalton.

24. (Original) The composition of claim 20, wherein the poly(ethylene glycol) moiety has polydispersity value ($M_w/M_n$) of less than 1.20.

25. (Original) The composition of claim 16, wherein the peptide moiety is peptide monomer comprising a single peptide.

26. (Original) The composition of claim 16, wherein the peptide moiety is a peptide dimer comprising two peptides linked by a linker moiety.

27. (Original) The composition of claim 25 or 26, wherein each peptide comprises no more than 50 amino acid monomers.

28. (Original) The composition of claim 27, wherein each peptide comprises between about 10 and 25 amino acid monomers.

29. (Original) The composition of claim 16, wherein the peptide moiety comprises one or more peptides which bind to erythropoietin-receptors.

30. (Original) The composition of claim 16, wherein the peptide moiety comprises one or more peptides which bind to thrombopoietin-receptors.

31. (Original) The compound of claim 1, wherein

$\alpha = 2$;

$\gamma = \delta = \beta = \varepsilon = 0$; and

Y is CO.

32. (Original) The composition of claim 16, wherein

$\alpha = 2$;

$\gamma = \delta = \beta = \varepsilon = 0$; and

Y is CO.

33. (Original) The compound of claim 5 wherein the poly(ethylene glycol) moiety comprises at least one monomeric poly(ethylene glycol) chain.

34. (Original) The compound of claim 33 wherein each poly(ethylene glycol) chain has a molecular weight from 20 to 40 KDaltons.

35. (Original) The composition of 16 wherein the poly(ethylene glycol) moiety comprises at least one monomeric poly(ethylene glycol) chain.

36. (Original) The compound of claim 35 wherein each poly(ethylene glycol) chain has a molecular weight from 20 to 40 KDaltons.